Navigation Links
Covance Receives Highest Level of Phase I Accreditation
Date:7/30/2009

PRINCETON, N.J., July 30 /PRNewswire/ -- Covance Inc. today announced that it has received standard and supplementary accreditation for the conduct of clinical pharmacology in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA). This voluntary accreditation process provides clinical trial volunteers and sponsors with confidence that research facilities and studies meet the industry's highest safety standards.

This accreditation was awarded to Covance's clinical research unit in Leeds, United Kingdom, where the company conducts first-in-human studies, including trials requiring a review of risk factors by the Expert Advisory Group.

"Covance delivers the highest level of data quality and patient safety for first-in-human trials, which is confirmed by the MHRA accreditation," said Rob Aspbury, M.D., managing director, clinical research services, Covance. "As an industry leader in clinical pharmacology, Covance provides superior experience and expertise in study design and conduct to support today's increasingly complex first-in-human trials."

MHRA accreditation was introduced to ensure the highest level of patient safety for early clinical development by providing more information about trial facilities. The process includes formal routine inspections that provide additional scope and depth to existing procedures for good clinical practice inspections.

Covance's clinical pharmacology expertise includes full-time physicians, clinical pharmacologists, registered pharmacists and more than 30 Advanced Life Support (ALS) trained nurses. The industry leader in the conduct of clinical pharmacology studies, Covance offers more than 500 beds across nine Phase I clinics located in the United States, United Kingdom, and Switzerland.

About Covance
'/>"/>

SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
3. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
4. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
5. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
6. USC Keck School of Medicines Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
7. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
8. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
10. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
(Date:9/22/2014)... Inc. (NYSE MKT: CUR) announced that Jonathan D. ... long-term follow up data on the Phase I trial ... of amyotrophic lateral sclerosis (ALS or Lou Gehrig,s ... Symposium on ALS of the Foundation Andre-Delambre, in ... not open to the public, covered data up to ...
(Date:9/22/2014)... CENTER VALLEY, Pa. , Sept. 22, 2014 ... and delivering innovative solutions for medical and surgical ... has reached a deal with Munich ... distributor of Kick ® Navigation. This agreement ... maintain distribution for cross-disciplinary U.S. sales and all ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... N.J. , May 19 ... CardioTec, the first and only conference dedicated to addressing ... event, sponsored by Medical Product Outsourcing magazine, ... issues through a specialized agenda and extraordinary lineup of ...
... May 18 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... early termination of the waiting period under the Hart-Scott-Rodino ... previously announced sale of International Technidyne Corporation (ITC) to ...
Cached Medicine Technology:Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference 2Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference 3Thoratec Announces Early Termination of HSR Waiting Period for the Sale of ITC to Danaher Corporation 2
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... Diego CA (PRWEB) September 22, 2014 ... significantly expand its work to equip women around the ... on poverty. Through the Women Empowered (WE) Initiative ... will now join community-led groups to pool their savings, ... , “Women are the solution to ending poverty in ...
(Date:9/22/2014)... September 22, 2014 The New York ... of Surgery at the Icahn School of Medicine at ... York Group for Plastic Surgery gives residents of New ... a team of world-renowned plastic surgeons performing innovative reconstructive ... Salzberg, MD, who led NYGPS, was named the Director ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global leader ... , WHAT: The 10th annual Customer Response Summit ... the connected consumer. Constant change in technology and ... and opportunities for customer experience executives. The Summit ... network and learn from fellow attendees, speakers and ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... YORK, Oct. 8 "Fluoridation of drinking,water is scientifically ... initiative or program," says the Canadian Association of Physicians,for ... CAPE is Canada,s leading voice on environmental health issues., ... fluoridation of public,drinking water in several communities in Alberta, ...
... New interim guidance,that outlines how to become a ... U.S. Department of Health and Human Services., ... Safety Act),authorized the creation of PSOs to improve ... patient safety events. By providing both privilege,and confidentiality, ...
... appears to sustain insulin production in the newly diagnosed. ... have developed a vaccine that may change the way ... diagnosed with type 1 diabetes. , "By a very ... save [a person,s] own insulin secretion, which may be ...
... N.J., Oct. 8 Quest Diagnostics,Incorporated (NYSE: DGX ... services, announced today that its third-quarter,2008 results will be ... and that it will hold its quarterly conference call ... ET on that day., The public may access ...
... The following statement,of Matthew L. Myers was released today ... reports, R.J. Reynolds has announced plans to,test-market three new ... "fresh" and "mellow" flavors and have slick, colorful,packaging similar ... Orbs,these new products also carry the name of RJR,s ...
... HOLE, MA Osamu Shimomura, a senior scientist emeritus ... has been awarded the Nobel Prize in Chemistry for ... the most important tools in contemporary science and medicine ... Shimomura shares the prize, which was announced early today ...
Cached Medicine News:Health News:Physicians' Group Rejects Fluoridation 2Health News:HHS Issues Interim Guidance for Patient Safety Organizations 2Health News:New Vaccine May Help Type 1 Diabetics in Future 2Health News:New Vaccine May Help Type 1 Diabetics in Future 3Health News:Quest Diagnostics to Release Third Quarter 2008 Financial Results 2Health News:R.J. Reynolds' New Smokeless Products Will Appeal to Children and Show Need for FDA Regulation of Tobacco Products 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 3
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
DxRxValv contains tables and figures to summarize important clinical data and current professional society recommendations. This handy manual details precise, up-to-date information for diagnosis and...
... Dx/Rx: Coronary Thrombosis ... flowcharts which facilitate transformation ... protocols from static images ... support tools. Details precise, ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
Medicine Products: